Innovative therapeutics

Investors

SEC Filings

NASDAQBMRN
FormDescriptionDateFormat
SC 13GSchedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutionsJun 10, 2005View HTMLDownload DOCDownload PDF
DEFR14ADEFR14AJun 6, 2005View HTMLDownload DOCDownload PDFDownload XLS
SC 13D/AAmendment to a SC 13D filingJun 6, 2005View HTMLDownload DOCDownload PDFDownload XLS
8-KReport of unscheduled material events or corporate eventJun 1, 2005View HTMLDownload DOCDownload PDFDownload XLS
DEFA14AAdditional proxy soliciting materials - definitiveJun 1, 2005View HTMLDownload DOCDownload PDFDownload XLS
8-KReport of unscheduled material events or corporate eventJun 1, 2005View HTMLDownload DOCDownload PDFDownload XLS
DEFC14ADefinitive proxy statement in connection with contested solicitationsMay 23, 2005View HTMLDownload DOCDownload PDFDownload XLS
DEFA14AAdditional proxy soliciting materials - definitiveMay 23, 2005View HTMLDownload DOCDownload PDFDownload XLS
DEFC14ADefinitive proxy statement in connection with contested solicitationsMay 23, 2005View HTMLDownload DOCDownload PDFDownload XLS
CORRESPCorrespondence from the Filer to the SECMay 19, 2005View HTMLDownload DOCDownload PDFDownload XLS
PRER14AProxy soliciting materials. Revised preliminary materialMay 19, 2005View HTMLDownload DOCDownload PDFDownload XLS
PRRN14ANon-management revised preliminary proxy soliciting materialsMay 19, 2005View HTMLDownload DOCDownload PDFDownload XLS
PRRN14ANon-management revised preliminary proxy soliciting materialsMay 19, 2005View HTMLDownload DOCDownload PDFDownload XLS
3Initial filing by director officer or owner of more than ten percent.May 18, 2005View HTMLDownload DOCDownload PDF
8-KReport of unscheduled material events or corporate eventMay 18, 2005View HTMLDownload DOCDownload PDFDownload XLS
PRRN14ANon-management revised preliminary proxy soliciting materialsMay 17, 2005View HTMLDownload DOCDownload PDFDownload XLS
CORRESPCorrespondence from the Filer to the SECMay 16, 2005View HTMLDownload DOCDownload PDFDownload XLS
PRER14AProxy soliciting materials. Revised preliminary materialMay 16, 2005View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesMay 13, 2005View HTMLDownload DOCDownload PDF
8-KReport of unscheduled material events or corporate eventMay 12, 2005View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesMay 9, 2005View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMay 9, 2005View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMay 9, 2005View HTMLDownload DOCDownload PDF
SC 13D/AAmendment to a SC 13D filingMay 6, 2005View HTMLDownload DOCDownload PDFDownload XLS
10-QQuarterly report which provides a continuing view of a company's financial positionMay 5, 2005View HTMLDownload DOCDownload PDFDownload XLS
1-25      26-50      51-75      76-100      101-107

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Palynziq™
Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information